TRANSMITTAL LETTER

RECEIVED CENTRAL FAX DENTER

*********		•••	AUG 1 0 2008
In re Application of: Fredericus Antonius DIJCKS et al.		: Docket No.:	1997.312 C1
Serial No:	10/718.398	: Examiner:	Laura Stockton
Filing Date:	November 19, 2003	: Group Art Unit:	1626
Title: METHOD OF TREATING PSYCHIATRIC DISORDERS WITH In CHANNEL INHIBITOR		I hereby certify th	OF FACSIMILE TRANSMISSION at the attached correspondence ing faxed to 571-273-8300 to the r Patens August 10, 2006
Commissione P.O. Box 145 Alexandria, V			Lynn Brush
☑ Transmitte	ed herewith find the document(s) re	lated to this application	on:

- 1. TRANSMITTAL LETTER IN DUPLICATE;
- 2. RESPONSE;
- 3. CERTIFICATE OF FACSIMILE

☐ Applicant hereby	petitions for	an extension of time under 37 CFR 1.136 of
☐ One Month	(\$ 120.00)	☐ Two Months (\$ 450.00)

☐Three Months (\$

The total fee believed due is \$0.00. Please charge this amount and any other fees which may be due (including filing fees under 37 CFR 1.16 and processing fees under 37 CFR 1.17) to Deposit Account No. 01-1350. If an extension of time is required but has not been requested above, Applicant hereby petitions for an extension of time sufficient for the attached document(s) to be timely. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Susan Hen

Susan Hess

Attorney for Applicant(s)

Reg. No. 37,350

Akzo Nobel Inc.
Intellectual Property Dept.
7 Livingstone Avenue
Dobbs Ferry, NY 10522-3408
Tel No.: (973) 422-7474

TRANSMITTAL LETTER

AUG 1 0 200
: Docket No.; 1997.312 C1
Examiner: Laura Stockton
: Group Art Unit: 1626 :
CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that the attached correspondence (4) sheets is being faxed to 571-273-8300 to the Commissioner for Patens
on <u>August 10, 2006</u>
Lynn Brush

- ☑ Transmitted herewith find the document(s) related to this application:
 - 1. TRANSMITTAL LETTER IN DUPLICATE;
 - 2. RESPONSE;

Alexandria, VA 22313-1450

3. CERTIFICATE OF FACSIMILE

Applicant hereby	petitions for a	n extension of time under 37 CFR 1.136 of
☐ One Month	(\$ 120.00)	☐ Two Months (\$ 450.00)
☐Three Months	(\$1020.00)	☐ Four Months (\$1590.00)

The total fee believed due is \$0.00. Please charge this amount and any other fees which may be due (including filing fees under 37 CFR 1.16 and processing fees under 37 CFR 1.17) to Deposit Account No. 01-1350. If an extension of time is required but has not been requested above, Applicant hereby petitions for an extension of time sufficient for the attached document(s) to be timely. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Susan Hess

Attorney for Applicant(s)

Reg. No. 37,350

Susan Hess

Akzo Nobel Inc. Intellectual Property Dept. 7 Livingstone Avenue Dobbs Ferry, NY 10522-3408 Tel No.: (973) 422-7474

AUG 1 0 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fredericus Antonius DIJCKS et al.

Serial No:

10/718,398

Filing Date:

November 19, 2003

Title:

METHOD OF TREATING PSYCHIATRIC

DISORDERS WITH IN CHANNEL

INHIBITOR

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Docket No.:

1997.312 C1

Examiner:

Laura Stockton

Group Art Unit:

1626

CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that the attached correspondence (4) sheets is being faxed to 571-273-8300 to the Commissioner for Patens

on

August 10, 2006

Lynn Brush

RESPONSE

Sir:

This is in response to the Office Action dated July 10, 2006 having a shortened statutory one-month period for response which expires on August 10, 2006.

In the Office Action, the Examiner has alleged that the elected species,

2-(3-trifluoromethylphenyl)-alpha-2-propenyl-benzenemethanamine, is not embraced by formula (I) on pages 1-2 of the specification. The Examiner has also required Applicants to indicate where in the specification (page number and line number) support is found for the claimed utility of the elected species.

In response, Applicants note that in addition to the compounds of formula I described in the present specification on pages 1-2, the specification also describes other compounds of a formula (I). In this regard, the Examiner's attention is directed to page 58, the last line reciting "The present invention further includes the compounds of formula (I):-", page 59, and page 60, lines 1-17, which indicate the structure of these particular compounds of formula (I). The elected species falls within the scope of the compounds of formula I described on pages 58-60 wherein A is group (a); Y is CH; X is CH=CH; P and S are H; R₁ is trifluoromethyl; B is group (d); R₂ is NH₂ and R₃-R₅ are all H. Support for the claimed utility of the elected species is found in the specification on pages 74-78 (Example 1) and in particular. Table 1 showing data for the inhibition of the Ih activation rate constant for compounds similar to the elected species and Table 2 showing data of mice burying behavior for the elected species and similar compounds.

In view of the above, it is believed that the specification provides support for the claimed utility of the elected species and that the reply of April 28, 2006 was fully responsive.

A good faith effort has been made to place the present application in condition for allowance. If the Examiner believes a telephone conference would be of value, she is requested to call the undersigned at the number listed below.

Respectfully submitted,

Susan Hess

Susan Hess.

Attorney for Applicants Reg. No. 37,350

(973) 422-7474

Akzo Nobel Inc. Intellectual Property Department 7 Livingston Avenue Dobbs Ferry, NY 10522-3408

Date: August 10, 2006